{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:57:51Z","timestamp":1781333871288,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejso.2026.111880","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:25:19Z","timestamp":1778552719000},"page":"111880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and the role of GnRHa in premenopausal HR+\/HER2+ breast cancer achieving pathologic complete response after neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Su Min","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Ki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Jung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Byul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-1783","authenticated-orcid":false,"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejso.2026.111880_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111880_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111880_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9938","key":"10.1016\/j.ejso.2026.111880_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ejso.2026.111880_bib5","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111880_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111880_bib7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111880_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10147-022-02115-x","article-title":"The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study","volume":"27","author":"Han","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111880_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejso.2026.111880_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"issue":"16","key":"10.1016\/j.ejso.2026.111880_bib11","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-Positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111880_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","article-title":"Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study","volume":"187","author":"O'Shaughnessy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ejso.2026.111880_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.6004\/jnccn.2025.0053","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 5.2025","volume":"23","author":"Gradishar","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.ejso.2026.111880_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111880_bib15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2026.111880_bib16","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.23.01935","article-title":"Optimizing postneoadjuvant treatment in patients with early breast cancer achieving pathologic complete response","volume":"42","author":"Valenza","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111880_bib17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/GO.20.00257","article-title":"Clinicopathologic features predictive of distant metastasis in patients diagnosed with invasive breast cancer","volume":"6","author":"Ali","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111880_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/bjc.2015.34","article-title":"A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer","volume":"112","author":"Boutros","year":"2015","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2026.111880_bib19","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejso.2026.111880_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molmed.2010.07.001","article-title":"Circulating tumour cells in cancer patients: challenges and perspectives","volume":"16","author":"Pantel","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ejso.2026.111880_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1019925","article-title":"Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111880_bib22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","article-title":"Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial","volume":"7","author":"Symmans","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111880_bib23","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/s41467-025-57293-9","article-title":"Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies","volume":"16","author":"Callari","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ejso.2026.111880_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70852","article-title":"Characterisation of HER2-Driven morphometric signature in breast cancer and prediction of risk of recurrence","volume":"14","author":"Atallah","year":"2025","journal-title":"Cancer Med"},{"issue":"35","key":"10.1016\/j.ejso.2026.111880_bib25","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.19.00443","article-title":"Incidence of late relapses in patients with HER2-Positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (alliance) and NRG Oncology\/NSABP B-31","volume":"37","author":"Chumsri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2026.111880_bib26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejso.2026.111880_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-023-00509-2","article-title":"Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial","volume":"9","author":"Dieci","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejso.2026.111880_bib28","article-title":"Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy","author":"Shai","year":"2025","journal-title":"Breast"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:47:42Z","timestamp":1781333262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0748798326004993"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111880","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors and the role of GnRHa in premenopausal HR+\/HER2+ breast cancer achieving pathologic complete response after neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111880"}}